Mony J. de Leon
Cornell University
Internal medicineEndocrinologyPathologyMagnetic resonance imagingOncologyHippocampal formationPsychologyNeuroscienceCognitionPositron emission tomographyDiseaseDementiaCerebrospinal fluidHippocampusAtrophyCognitive impairmentAlzheimer's diseaseNeuroimagingMedicineBiomarker (medicine)
304Publications
86H-index
23.5kCitations
Publications 302
Newest
#1Julia Neitzel (LMU: Ludwig Maximilian University of Munich)H-Index: 11
#2Nicolai Franzmeier (LMU: Ludwig Maximilian University of Munich)H-Index: 18
Last. William J. JagustH-Index: 140
view all 0 authors...
Klotho-VS heterozygosity (KL-VShet) is associated with reduced risk of Alzheimer’s disease (AD). However, whether KL-VShet is associated with lower levels of pathologic tau, i.e., the key AD pathology driving neurodegeneration and cognitive decline, is unknown. Here, we assessed the interaction between KL-VShet and levels of beta-amyloid, a key driver of tau pathology, on the levels of PET-assessed neurofibrillary tau in 551 controls and patients across the AD continuum. KL-VShet showed lower cr...
Source
#1Tracy Butler (Cornell University)H-Index: 27
#2Judith D. Goldberg (NYU: New York University)H-Index: 66
Last. Craig S. Atwood (UW: University of Wisconsin-Madison)H-Index: 67
view all 0 authors...
The LUCINDA Trial (Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's) is a 52 week, randomized, placebo-controlled trial of leuprolide acetate (Eligard) in women with Alzheimer's disease (AD). Leuprolide acetate is a gonadotropin analogue commonly used for hormone-sensitive conditions such as prostate cancer and endometriosis. This repurposed drug demonstrated efficacy in a previous Phase II clinical trial in those women with AD who also received a stable dose...
Source
#1Erica F. Barry (Cornell University)H-Index: 4
#2John P. Loftus (Cornell University)H-Index: 11
Last. Philippa J Johnson (Cornell University)H-Index: 4
view all 6 authors...
Abstract White matter dysfunction and degeneration have been a topic of great interest in healthy and pathological aging. While ex vivo studies have investigated age-related changes in canines, little in vivo canine aging research exists. Quantitative diffusion MRI such as diffusion tensor imaging (DTI) has demonstrated aging and neurodegenerative white matter changes in humans. However, this method has not been applied and adapted in vivo to canine populations. This study aimed to test the hypo...
Source
#1Russell H. Swerdlow (KU: University of Kansas)H-Index: 75
#2Mony J. de Leon (Cornell University)H-Index: 86
Last. David L. Marcus (NYU: New York University)H-Index: 14
view all 3 authors...
Background Alzheimer's disease (AD) features perturbed brain glucose utilization, which could contribute to brain bioenergetic failure. This led some to consider using ketone bodies to enhance AD brain bioenergetics and treat AD. Objective We evaluated the rate at which brain homogenates from persons with Alzheimer's disease (AD) metabolize D-β-hydroxybutyrate (BHB). Methods We homogenized pieces of temporal cortex from frozen autopsy brains obtained from recently deceased AD subjects (n = 4), a...
Source
Background Periodontal disease is an inflammatory, dysbiotic condition. Studies have shown that in the elderly, periodontal disease was associated with cognitive dysfunction and Alzheimer's disease. Objective To investigate whether young healthy subjects with periodontal disease have lower cognition compared to those without periodontal disease. The salivary cytokines (IL-1β, TNF-α) levels in relation to cognition were also tested. Methods In a monocenter, cross-sectional study, forty subjects [...
Source
#1Omonigho M BubuH-Index: 8
#2Ogie Queen Umasabor-Bubu (SUNY Downstate Medical Center)H-Index: 4
view all 17 authors...
INTRODUCTION Obstructive sleep apnea (OSA) is associated with Alzheimer's disease (AD) biomarkers in cognitively normal (CN) and mild cognitive impaired (MCI) participants. However, independent and combined effects of OSA, amyloid beta (Aβ) and tau-accumulation on AD time-dependent progression risk is unclear. METHODS Study participants grouped by biomarker profile, as described by the A/T/N scheme, where "A" refers to aggregated Aβ, "T" aggregated tau, and "N" to neurodegeneration, included 258...
1 CitationsSource
#1Lisa MosconiH-Index: 58
#2Valentina BertiH-Index: 18
Last. Silky PahlajaniH-Index: 1
view all 17 authors...
Source
#1Angela R. Kamer (NYU: New York University)H-Index: 19
#2Smruti Pushalkar (NYU: New York University)H-Index: 12
Last. Mony J. de Leon (Cornell University)H-Index: 86
view all 13 authors...
Introduction Periodontal disease is a chronic, inflammatory bacterial dysbiosis that is associated with both Alzheimer's disease (AD) and Down syndrome. Methods A total of 48 elderly cognitively normal subjects were evaluated for differences in subgingival periodontal bacteria (assayed by 16S rRNA sequencing) between cerebrospinal fluid (CSF) biomarker groups of amyloid and neurofibrillary pathology. A dysbiotic index (DI) was defined at the genus level as the abundance ratio of known periodonta...
Source
#1Jerzy WegielH-Index: 57
#2Michael FloryH-Index: 17
Last. Barry Reisberg (NYU: New York University)H-Index: 89
view all 10 authors...
Clinical and neuropathological staging of Alzheimer's disease (AD) neurodegeneration and neuronal loss dynamics is the baseline for identification of treatment targets and timing. The aim of this study of 14 brain regions in 25 subjects diagnosed with AD and 13 age-matched control subjects was to establish the pattern of neurodegeneration, and the severity and rate of neuronal loss in mild cognitive impairment/mild AD (Functional Assessment Staging [FAST] test 3-4), moderate to moderately severe...
Source
#1Tracy Butler (Cornell University)H-Index: 27
#2Craig S. Atwood (UW: University of Wisconsin-Madison)H-Index: 67
view all 7 authors...
Source